Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1.
Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, Vargeese C, Gomez A, Bouhana K, Aitchison R, Pavco P, Campochiaro PA. Shen J, et al. Among authors: aitchison r. Gene Ther. 2006 Feb;13(3):225-34. doi: 10.1038/sj.gt.3302641. Gene Ther. 2006. PMID: 16195704
Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Aitchison R, Erlich SS; MONET Clinical Study Group. Nguyen QD, et al. Among authors: aitchison r. Ophthalmology. 2012 Sep;119(9):1867-73. doi: 10.1016/j.ophtha.2012.03.043. Epub 2012 Jun 8. Ophthalmology. 2012. PMID: 22683252 Clinical Trial.
Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients.
Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Khan A, Aitchison R, Erlich SS; PF-04523655 Study Group. Nguyen QD, et al. Among authors: aitchison r. Eye (Lond). 2012 Aug;26(8):1099-105. doi: 10.1038/eye.2012.106. Epub 2012 May 25. Eye (Lond). 2012. PMID: 22627477 Free PMC article. Clinical Trial.
Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study).
Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Aitchison R, Erlich SS; DEGAS Clinical Study Group. Nguyen QD, et al. Among authors: aitchison r. Invest Ophthalmol Vis Sci. 2012 Nov 15;53(12):7666-74. doi: 10.1167/iovs.12-9961. Invest Ophthalmol Vis Sci. 2012. PMID: 23074206 Clinical Trial.
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D. Jiang Y, et al. Among authors: aitchison r. Arthritis Rheum. 2000 May;43(5):1001-9. doi: 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P. Arthritis Rheum. 2000. PMID: 10817552 Free article. Clinical Trial.
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P. Bresnihan B, et al. Among authors: aitchison r. Arthritis Rheum. 1998 Dec;41(12):2196-204. doi: 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2. Arthritis Rheum. 1998. PMID: 9870876 Clinical Trial.
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Kobayashi H, Eckhardt SG, Lockridge JA, Rothenberg ML, Sandler AB, O'Bryant CL, Cooper W, Holden SN, Aitchison RD, Usman N, Wolin M, Basche ML. Kobayashi H, et al. Cancer Chemother Pharmacol. 2005 Oct;56(4):329-36. doi: 10.1007/s00280-004-0968-x. Epub 2005 May 20. Cancer Chemother Pharmacol. 2005. PMID: 15906031 Clinical Trial.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Clinical Trial.
The future of clinical trials and drug development: 2050.
Hardman TC, Aitchison R, Scaife R, Edwards J, Slater G. Hardman TC, et al. Among authors: aitchison r. Drugs Context. 2023 Jun 8;12:2023-2-2. doi: 10.7573/dic.2023-2-2. eCollection 2023. Drugs Context. 2023. PMID: 37313038 Free PMC article.
65 results